Primary Myelofibrosis (DIPSS-Plus stratified) · line 2 · Fedratinib (Inrebic) for ruxolitinib-resistant / intolerant PMF

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-FEDRATINIB-PMF`

ID	`IND-PMF-2L-FEDRATINIB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-PMF`
Sources	`SRC-DIPSS-PLUS-GANGAT-2011` `SRC-ESMO-MPN-2015` `SRC-JAKARTA2-HARRISON-2017` `SRC-NCCN-MPN-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for ruxolitinib-resistant/intolerant MF. Wernicke encephalopathy boxed warning dominant safety concern. Ukraine access constraint.

Used By

Algorithms

ALGO-PMF-2L - ALGO-PMF-2L